Use of aminopyridine in the treatment of fatigue

DE102022126035B4Active Publication Date: 2026-07-16ALFRED E TIEFENBACHER (GMBH & CO KG)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE102022126035
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-10-07
Publication Date
2026-07-16
Estimated Expiration
2042-10-07

AI Technical Summary

Technical Problem

Current treatments for fatigue associated with viral infections, particularly post-COVID-19 syndrome and chronic fatigue syndrome, lack clear scientific results and reliable laboratory parameters, and existing therapies do not effectively address the persistent and disproportionate exhaustion experienced by patients.

Method used

The use of pyridine-3,4-diamine and its derivatives, or physiologically tolerated salts, to prevent potassium ions from leaving nerve cells, thereby prolonging depolarization and increasing acetylcholine release, which improves muscle contraction and reduces fatigue symptoms.

Benefits of technology

Aminopyridine derivatives provide immediate and significant improvement in fatigue symptoms, including reduced sleep requirements and enhanced physical and mental resilience, as demonstrated in case studies, with potential for long-term treatment to achieve a Bell score of up to 100, improving quality of life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Use of pyridine-3,4-diamine or a physiologically acceptable salt thereof in the prevention and / or treatment of fatigue associated with viral infection caused by ss(+)RNA viruses of the family Coronavriridae including the virus SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKU1, HCoV-OC43, HCoV-NL63 and / or HCoV-229E.
Need to check novelty before this filing date? Find Prior Art